Sequoia Vaccines Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • IPO
  • (Cancelled)

  • Latest Deal Amount
  • $25M

  • Investors
  • 5

Sequoia Vaccines General Information

Description

Sequoia Vaccines Inc is a clinical stage pharmaceutical company developing a vaccine designed to prevent recurrent urinary tract infections (UTIs) and small molecules treating cancers and bacterial infections. Its current vaccine SEQ-400, is a vaccine for the prevention of recurrent UTIs.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 11775 Borman Drive
  • Suite 100
  • Saint Louis, MO 63146
  • United States
+1 (314)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 11775 Borman Drive
  • Suite 100
  • Saint Louis, MO 63146
  • United States
+1 (314)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sequoia Vaccines Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. IPO 05-May-2025 $25M Cancelled Clinical Trials - Phase 1
7. Later Stage VC 30-Dec-2020 Completed Clinical Trials - Phase 1
6. Later Stage VC 01-Feb-2017 Completed Clinical Trials - Phase 1
5. Seed Round 19-May-2016 Completed Clinical Trials - Phase 1
4. Later Stage VC 30-Nov-2012 Completed Clinical Trials - Phase 1
3. Later Stage VC Completed Clinical Trials - Phase 1
2. Later Stage VC 01-Dec-2010 $389K $389K Completed Clinical Trials - Phase 1
1. Grant 01-Jan-2009 $1.73M Completed Startup
To view Sequoia Vaccines’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Sequoia Vaccines Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Sequoia Vaccines Inc is a clinical stage pharmaceutical company developing a vaccine designed to prevent recurrent urina
Drug Discovery
Saint Louis, MO
5 As of 2024

Wayne, PA
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Sequoia Vaccines Competitors (3)

One of Sequoia Vaccines’s 3 competitors is Aclaris Therapeutics, a Formerly VC-backed company based in Wayne, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aclaris Therapeutics Formerly VC-backed Wayne, PA
ArsenalBio Venture Capital-Backed South San Francisco, CA
Pliant Therapeutics Formerly VC-backed San Francisco, CA
You’re viewing 3 of 3 competitors. Get the full list »

Sequoia Vaccines Patents

Sequoia Vaccines Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-9562031-B1 Phenethyldihydrobenzodioxolones and methods of use Active 12-Sep-2015
WO-2017044877-A1 Phenethyldihydrobenzodioxolones and methods of use Inactive 12-Sep-2015
US-20170073324-A1 Bifidenone compositions and methods of use Inactive 11-Sep-2015
CA-2923834-A1 Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections Pending 17-Mar-2015
EP-3069729-A1 Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections Inactive 17-Mar-2015 A61K39/0258
To view Sequoia Vaccines’s complete patent history, request access »

Sequoia Vaccines Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sequoia Vaccines Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cultivation Capital Venture Capital Minority
Holton Capital Group Asset Manager Minority
Prolog Ventures Venture Capital Minority
St. Louis Arch Angels Angel Group Minority
U.S. Department of Health and Human Services Government
To view Sequoia Vaccines’s complete investors history, request access »

Sequoia Vaccines FAQs

  • When was Sequoia Vaccines founded?

    Sequoia Vaccines was founded in 1999.

  • Where is Sequoia Vaccines headquartered?

    Sequoia Vaccines is headquartered in Saint Louis, MO.

  • What is the size of Sequoia Vaccines?

    Sequoia Vaccines has 5 total employees.

  • What industry is Sequoia Vaccines in?

    Sequoia Vaccines’s primary industry is Drug Discovery.

  • Is Sequoia Vaccines a private or public company?

    Sequoia Vaccines is a Private company.

  • What is the current valuation of Sequoia Vaccines?

    The current valuation of Sequoia Vaccines is .

  • What is Sequoia Vaccines’s current revenue?

    The current revenue for Sequoia Vaccines is .

  • How much funding has Sequoia Vaccines raised over time?

    Sequoia Vaccines has raised $77.7M.

  • Who are Sequoia Vaccines’s investors?

    Cultivation Capital, Holton Capital Group, Prolog Ventures, St. Louis Arch Angels, and U.S. Department of Health and Human Services have invested in Sequoia Vaccines.

  • Who are Sequoia Vaccines’s competitors?

    Aclaris Therapeutics, ArsenalBio, and Pliant Therapeutics are competitors of Sequoia Vaccines.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process